Tvardi Therapeutics, Inc. - Common Stock (TVRD)
5.0000
+1.9000 (61.29%)
NASDAQ· Last Trade: Jul 8th, 6:55 PM EDT
Here are the top movers in Wednesday's session.chartmill.com
Via Chartmill · July 8, 2026
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics (NASDAQ:TVRD)
Via Benzinga · July 8, 2026
The trading volume of these stocks is deviating from the norm in today's session.chartmill.com
Via Chartmill · July 8, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · July 8, 2026
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.chartmill.com
Via Chartmill · July 7, 2026
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics (NASDAQ:TVRD)
Via Benzinga · July 7, 2026
Top stock movements in today's session.chartmill.com
Via Chartmill · July 7, 2026
The trading volume of these stocks is deviating from the norm in today's session.chartmill.com
Via Chartmill · June 30, 2026
Get insights into the top gainers and losers of Wednesday's pre-market session.chartmill.com
Via Chartmill · December 31, 2025
In today's session, these stocks are experiencing unusual volume.
Via Chartmill · October 20, 2025
Unusual volume stocks are being observed in Thursday's session.
Via Chartmill · October 16, 2025
Which stocks have an unusual volume on Wednesday?
Via Chartmill · October 15, 2025
Via Benzinga · October 14, 2025
Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response.
Via Benzinga · October 13, 2025
Via Benzinga · October 13, 2025
Via Benzinga · October 13, 2025
The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review of exploratory efficacy.
Via Stocktwits · October 13, 2025
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026.
Via Benzinga · June 12, 2025
Via Benzinga · June 12, 2025
Via Benzinga · April 25, 2025
